Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC

09 August 2024

Angiex’s AGX101 Phase I Study Receives Critical Support from Abzena

Angiex has made significant strides in its Phase I study of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to treat aggressive cancers by targeting tumor blood vessels. Abzena, a leading biopharmaceutical services provider, plays an essential role in supporting the trial by supplying the critical clinical trial materials necessary to advance this innovative therapy.

Clinical Research News recently covered the collaboration, highlighting how Abzena’s expertise in cGMP manufacturing has enabled Angiex to progress AGX101 through clinical development. As a leading outlet for news on clinical trials and research innovation, Clinical Research News emphasizes the importance of partnerships like that between Angiex and Abzena in accelerating the development of novel cancer treatments. Their coverage underscores the growing promise of ADC therapies in addressing unmet needs in oncology.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch